MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Boston Scientific Corp.

Abierto

SectorSanidad

101.25 0.73

Resumen

Variación precio

24h

Actual

Mínimo

100.42

Máximo

101.95

Métricas clave

By Trading Economics

Ingresos

-138M

562M

Ventas

352M

4.6B

P/B

Media del Sector

74.864

57.333

BPA

0.7

Margen de beneficios

12.322

Empleados

53,000

EBITDA

-41M

1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+18.99% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-14B

138B

Apertura anterior

100.52

Cierre anterior

101.25

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Boston Scientific Corp. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2025, 12:16 UTC

Ganancias
Principales Movimientos del Mercado

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 mar 2025, 12:35 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 feb 2025, 12:23 UTC

Ganancias

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23 abr 2025, 10:32 UTC

Ganancias

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 abr 2025, 10:31 UTC

Ganancias

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific 1Q EPS 45c >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific 1Q Adj EPS 75c >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific 1Q Sales $4.66B >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 abr 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 mar 2025, 11:59 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mar 2025, 11:58 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mar 2025, 11:58 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb 2025, 21:33 UTC

Ganancias

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 15:20 UTC

Ganancias

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 11:39 UTC

Ganancias

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 feb 2025, 11:39 UTC

Ganancias

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 feb 2025, 11:38 UTC

Ganancias

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 feb 2025, 11:38 UTC

Ganancias

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific 4Q Adj EPS 70c >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific 4Q Sales $4.56B >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 feb 2025, 11:37 UTC

Ganancias

Boston Scientific 4Q EPS 38c >BSX

Comparación entre iguales

Cambio de precio

Boston Scientific Corp. previsión

Precio Objetivo

By TipRanks

18.99% repunte

Estimación a 12 Meses

Media 120.35 USD  18.99%

Máximo 135 USD

Mínimo 110 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Boston Scientific Corp. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

23 ratings

22

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

95.25 / 102.37Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.